- Pyelonephritis, a severe bacterial infection of the kidneys, is increasingly recognized as a critical urological condition requiring timely and effective treatment through antibiotics or surgical interventions in complicated cases. The growing prevalence of urinary tract infections (UTIs), antibiotic-resistant pathogens, and recurrent kidney infections in both hospital and community settings is driving demand for targeted treatment solutions
- The rising global burden of healthcare-associated infections (HAIs), along with increasing awareness about early diagnosis and prompt antibiotic treatment, is significantly fueling market growth. The demand is further supported by a growing elderly population and patients with comorbidities such as diabetes, which increases susceptibility to kidney infections
- North America dominates the pyelonephritis treatment market, accounting for the largest revenue share of 38.7% in 2024, attributed to high healthcare spending, robust antibiotic stewardship programs, and advanced diagnostic infrastructure. The U.S. leads the regional market due to a high incidence of complicated UTIs and proactive public health initiatives aimed at managing antimicrobial resistance
- Asia-Pacific is projected to be the fastest-growing region in the pyelonephritis treatment market during the forecast period, driven by increasing access to healthcare services, growing awareness of UTI complications, and rising investments in infectious disease management across countries like India, China, and Southeast Asia
- The medication segment expect to dominate the treatment landscape, accounting for approximately 78.4% of the global pyelonephritis treatment market in 2024, with antibiotics such as Plazomicin, Levofloxacin, and Meropenem-Vaborbactam holding a significant share due to their efficacy against multidrug-resistant pathogens and their widespread use as first-line treatments in acute cases.
